Biogen buys midphase drug to challenge Roche for stroke market

Biogen is exercising its option to acquire an acute ischemic stroke candidate from TMS after getting a look at phase 2a data. The results persuaded Biogen to pay $18 million for a small molecule that may expand the time window in which thrombolytics can safely be used to clear clots.